Back to Project Library

In Sub-Saharan Africa, the World Health Organization reported the prevalence of ~95% positive malaria cases–-76% within children under the age of five. Currently, malaria tests for the P. falciparum strain have provided an abundance of false negatives, due to a gene deletion occurring on the HRP2 protein gene. Our solution to this issue is the detection of the Plasmodium falciparum lactate dehydrogenase (PfLDH) protein prevalence using Bim-Bcl2 LOCKR proteins. We plan to use luminescence as a biomarker to identify the abundance of PfLDH proteins present in malaria. This will be completed through modifying LOCKR to bind to PfLDH and “open.” A sandwich assay structure will form where a primary capture agent binds to the PfLDH biomarker. When the aptamer binds to the PfLDH, the nanoclusters conformationally change, emitting fluorescence. In essence, this LOCKR system will be developed through a multistep framework. Paired alongside a coffee-ring amplification mechanism, this engineered test is portable and provides results within 15 to 30 minutes, requiring no highly-skilled personnel. This allows our LOCKR diagnostic to be used in underdeveloped countries, mainly in Sub-Saharan Africa. The use of small blood samples (below 5 µL) allows this innovation to be cost-effective and globally accessible.

Detecting Malaria through De Novo LOCKR Design

School

Denmark High School
Alpharetta, GA

BioBuilderClub Season

2025-2026 Season

Category

Resources

Poster

Lightning Talk Slide

Abstract